Charles River Laboratories (CRL) said Wednesday it and Medipost have signed a memorandum of understanding to collaborate on GMP-compliant testing.
Financial terms weren't disclosed.
Under the MoU, Charles River will offer its services related to biologics quality control, viral testing, release testing, and other GMP-compliant services for the support of Medipost's cell therapy pipeline, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments